Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8212610 | 0.85 | PLA2G10 (0.50) | PLA2G10CTSKPLA2G2ASMN1; SMN2RAB9A | |
| SCHEMBL10058366 | 0.84 | CASP1 (0.49) | CTSKLMNATSHRKMT2A | |
| SCHEMBL3590845 | 0.81 | MTNR1A (0.49) | PLA2G10PLA2G2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL553506 | 0.81 | MTNR1A (0.49) | PLA2G10PLA2G2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL24698678 | 0.81 | ATM (0.46) | PLA2G10CTSKMTNR1AMTNR1BTSHR | |
| SCHEMBL19145291 | 0.80 | ALDH1A1 (0.41) | PLA2G10PLA2G2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19145283 | 0.79 | ALDH1A1 (0.44) | PLA2G10CTSKPLA2G2ASMN1; SMN2RAB9A | |
| SCHEMBL19014942 | 0.78 | PLA2G10 (0.45) | PLA2G10CTSKPLA2G2ATSHR | |
| SCHEMBL19145104 | 0.78 | P2RY12 (0.40) | PLA2G10SMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL19145109 | 0.77 | ALDH1A1 (0.41) | PLA2G10PLA2G2ASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| WO-2009036051-A1 | BCL-2 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036035-A1 | BCL-2 INHIBITORS | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | PLA2G10 4296/4885CTSK 1656/4885PLA2G2A 3487/4885 |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | PLA2G10 4423/4885CTSK 2195/4885PLA2G2A 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.